PMID- 12394191
OWN - NLM
STAT- MEDLINE
DCOM- 20030501
LR  - 20191025
IS  - 0960-8931 (Print)
IS  - 0960-8931 (Linking)
VI  - 12
IP  - 5
DP  - 2002 Oct
TI  - Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with 
      the Melan-A peptide analogue A27L: a qualitative analysis.
PG  - 491-8
AB  - Modifications in tumour antigen-derived epitopes that stabilize the major 
      histocompatibility complex (MHC)-peptide complex result in enhanced stimulatory 
      capacity and improved immunogenicity of the altered peptide. These epitope 
      analogues are attractive candidates for the development of peptide-based vaccine 
      trials. Any modification, however, in tumour antigens may induce T-cell responses 
      that could either fail to react against the naturally occurring peptides or 
      represent only a subset of the total antigen-specific repertoire. In the present 
      study, we performed a critical analysis of the ability of cytotoxic T-lymphocyte 
      (CTL) clones, derived from two melanoma patients through stimulation with the 
      A27L peptide analogue, to cross-react with the naturally processed Melan-A/MART-1 
      (Melan-A) peptides in terms of T-cell receptor (TCR) affinity, functional avidity 
      and fine antigen specificity. We found that all the A27L-specific clones analysed 
      possessed a very low avidity for the natural Melan-A peptides, and that their 
      binding affinity for human leukocyte antigen (HLA) tetramers complexed with both 
      the modified and the natural Melan-A peptides did not strictly correlate with 
      their functional avidity. We also observed that these clones were able to 
      cross-recognize both natural Melan-A peptides in one patient, but only one 
      peptide in the second patient. We discuss the capability of the A27L peptide 
      analogue to stimulate all the available Melan-A-specific repertoire.
FAU - Palermo, B
AU  - Palermo B
AD  - Experimental Immunology, IRCCS Maugeri Foundation, Pavia, Italy.
FAU - Campanelli, R
AU  - Campanelli R
FAU - Garbelli, S
AU  - Garbelli S
FAU - Mantovani, S
AU  - Mantovani S
FAU - Robustelli Della Cuna, G
AU  - Robustelli Della Cuna G
FAU - Necker, A
AU  - Necker A
FAU - Manganoni, A M
AU  - Manganoni AM
FAU - Carella, G
AU  - Carella G
FAU - Rivoltini, L
AU  - Rivoltini L
FAU - Lantelme, E
AU  - Lantelme E
FAU - Giachino, C
AU  - Giachino C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (MART-1 Antigen)
RN  - 0 (MLANA protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Antibody Affinity
MH  - Antigens, Neoplasm
MH  - Cancer Vaccines/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Flow Cytometry
MH  - HLA Antigens/metabolism
MH  - Humans
MH  - MART-1 Antigen
MH  - Melanoma/immunology/*therapy
MH  - Neoplasm Proteins/*chemistry/genetics/*pharmacology
MH  - Peptides/chemistry/*pharmacology
MH  - Protein Binding
MH  - Receptors, Antigen, T-Cell/metabolism
MH  - T-Lymphocytes, Cytotoxic/*cytology/metabolism
EDAT- 2002/10/24 04:00
MHDA- 2003/05/02 05:00
CRDT- 2002/10/24 04:00
PHST- 2002/10/24 04:00 [pubmed]
PHST- 2003/05/02 05:00 [medline]
PHST- 2002/10/24 04:00 [entrez]
AID - 10.1097/00008390-200209000-00011 [doi]
PST - ppublish
SO  - Melanoma Res. 2002 Oct;12(5):491-8. doi: 10.1097/00008390-200209000-00011.